Immune surveillance activation after neoadjuvant therapy for esophageal adenocarcinoma and complete response

After neoadjuvant chemoradiotherapy for esophageal adenocarcinoma, up to 29% of patients have a pathological complete response (pCR). What to do afterward is still under debate. The aim of this prospective study was to define which local markers of immune response might act as predictors of pCR and...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncoimmunology
Autores principales: Kotsafti, Andromachi, Scarpa, Melania, Cavallin, Francesco, Fassan, Matteo, Salmaso, Roberta, Porzionato, Andrea, Saadeh, Luca, Cagol, Matteo, Alfieri, Rita, Castoro, Carlo, Rugge, Massimo, Castagliuolo, Ignazio, Scarpa, Marco
Formato: Artigo
Lenguaje:Inglês
Publicado: Taylor & Francis 2020
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7458640/
https://ncbi.nlm.nih.gov/pubmed/32923165
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2020.1804169
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares